We are live on ! Find out more
ALNY icon

Alnylam Pharmaceuticals

238 hedge funds and large institutions have $6.73B invested in Alnylam Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 43 funds opening new positions, 107 increasing their positions, 58 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

192% more capital inflows, than outflows

Capital inflows: $1B | Capital outflows: $342M

105% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 21

84% more repeat investments, than reductions

Existing positions increased: 107 | Existing positions reduced: 58

33% more call options, than puts

Call options by funds: $84.9M | Put options by funds: $63.7M

20% more funds holding in top 10

Funds holding in top 10: 10 → 12 (+2)

10% more funds holding

Funds holding: 216 → 238 (+22)

7.25% more ownership

Funds ownership: 69.25% → 76.5% (+7.3%)

Holders
238
Holders Change
+22
Holders Change %
+10.19%
% of All Funds
6.31%
Holding in Top 10
12
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+20%
% of All Funds
0.32%
New
43
Increased
107
Reduced
58
Closed
21
Calls
$84.9​M
Puts
$63.7​M
Net Calls
+$21.2​M
Net Calls Change
-⁠$1.74​M

ALNY Hedge Fund Activity: Q1 2015 in Review

238 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q1 2015, worth a combined $6.73B — up 20% from $5.63B a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new ALNY positions and 21 closed out — a net gain of 22 holders — while 107 added to existing stakes and 58 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $151M. The largest seller was Franklin Resources, cutting an estimated $103M.

  • 238 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q1 2015, up from 216 in Q4 2014.
  • Funds reported $6.73B of Alnylam Pharmaceuticals stock for Q1 2015, up 20% quarter-over-quarter.
  • 43 funds opened new Alnylam Pharmaceuticals positions in Q1 2015 and 21 closed out, a net change of +22 holders.
  • The largest Alnylam Pharmaceuticals buyer in Q1 2015 was Wellington Management Group, an estimated $151M added.
  • The largest Alnylam Pharmaceuticals seller in Q1 2015 was Franklin Resources, an estimated $103M sold.

Based on aggregated 13F filings for Q1 2015.